Previous studies have demonstrated that the combination of photodynamic therapy, photothermal therapy and chemotherapy is highly effective in treating hepatocellular carcinoma (HCC). However, the clinical application of this approach has been hindered by the lack of efficient and low-toxicity drug delivery platforms. To address this issue, we developed a novel biomimetic nanocarrier platform named ZID@RM, which utilizes ZIF8 functional nanoparticles encapsulated with macrophage membrane and loaded with indocyanine green and doxorubicin. The bionic nanocarrier platform has good biocompatibility, reducing the risk of rapid clearance by macrophages and improving the targeting ability for HCC cells. Under the dual regulation of acidity and infrared light, ZID@RM stimulated the generation of abundant reactive oxygen species within HCC cells, induced tumor cell pyroptosis and promoted the release of damage-associated molecular patterns to induce immune responses. In the future, this technology platform has the potential to provide personalized and improved healthcare by using patients' own macrophage membranes to create an efficient drug delivery system for tumor therapy.Graphical abstract Scheme 1 Schematic representation of the synthesis of a biomimetic nanomedicine delivery platform (ZID@RM) and its application in tumor imaging-guided combination therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s13346-024-01690-y | DOI Listing |
Mol Pharm
January 2025
Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Developing low-toxicity, high-efficacy, and fast-acting strategies to manage acute liver injury (ALI) is critical due to its rapid progression and potential for severe outcomes. Curcumin (CUR) has shown promise in ALI therapy due to its ability to modulate the inflammatory microenvironment by scavenging reactive oxygen species (ROS). Nevertheless, CUR is highly hydrophobic limiting its bioavailability and effective in vivo transport, which hinders its further application.
View Article and Find Full Text PDFACS Omega
December 2024
Key Laboratory of Chemical Biology of Natural Products (Ministry of Education), Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong 250012, China.
The integration of different therapies to enhance the efficacy and minimize adverse reactions has become popular recently. This approach leverages the complementary mechanisms of action of different treatments, which can lead to better therapeutic outcomes and reduced side effects. Human serum albumin (HSA) exhibits excellent drug loading ability and is often used for biomimetic tumor delivery in multidrug nanocarriers.
View Article and Find Full Text PDFJ Control Release
January 2025
Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, School of Pharmacy, Yantai University, Yantai 264005, China. Electronic address:
Cisplatin (Cis), a potent chemotherapeutic agent, often causes acute kidney injury (AKI), limiting its clinical efficacy. RONS flares at the AKI site are a key factor in its progression. In this study, leveraging the advantages of cell membrane-coated biomimetic nanocarriers, we developed a multifunctional biomimetic nanodelivery system nano-RONS-sacrificial agent for AKI treatment.
View Article and Find Full Text PDFBeilstein J Nanotechnol
December 2024
Department of Immunology, Microbiology and Parasitology. Biological and Natural Sciences Institute. Federal University of Triângulo Mineiro. Uberaba, Minas Gerais, Brazil.
Biomimetic nanocarriers, engineered to mimic the characteristics of native cells, offer a revolutionary approach in the treatment of various complex human diseases. This strategy enhances drug delivery by leveraging the innate properties of cellular components, thereby improving biocompatibility and targeting specificity. Biomimetic nanocarriers demonstrate significant advancements in drug delivery systems against cancer therapy, Alzheimer's disease, autoimmune diseases, and viral infections such as COVID-19.
View Article and Find Full Text PDFJ Drug Target
January 2025
Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S Narsee Monjee Institute of Management Studies, Shirpur, India.
The occurrence of oral bone tissue degeneration and bone defects by osteoporosis, tooth extraction, obesity, trauma, and periodontitis are major challenges for clinicians. Traditional bone regeneration methods often come with limitations such as donor site morbidity, limitation of special shape, inflammation, and resorption of the implanted bone. The treatment oriented with biomimetic bone materials has achieved significant attention recently.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!